Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynogen Pharmaceuticals has acquired from Arachnova Therapeutics, all of its worldwide patent rights and know-how related to DDP225 in an asset purchase agreement.
Subscribe to our email newsletter
According to the company, the Arachnova patent rights, which include granted patents and pending applications related to the use of DDP225 for the treatment of functional bowel disorders, genitourinary (GU) disorders and pain, complement and enhance Dynogen’s existing extensive worldwide patent estate related to DDP225.
Mark Boshar, vice president for legal affairs and chief patent counsel of Dynogen, said: “Dynogen now owns 18 issued patents and more than 60 pending patent applications worldwide related to DDP225, and is well positioned to have market exclusivity for the commercialization of DDP225.”